

Alternative Approaches to Parasites and Natural Treatment Options

Type: Review Article

Received: June 22, 2026

Published: July 21, 2026

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Citation:

Christina Rahm. "Alternative Approaches to Parasites and Natural Treatment Options". PriMera Scientific Surgical Research and Practice 8.1 (2026): 39-43.

Copyright:

© 2026 Christina Rahm. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This white paper explores *natural and integrative strategies for managing parasitic infections*, which affect billions of people worldwide and remain a major global health challenge. While conventional antiparasitic drugs are essential, their effectiveness is increasingly limited by *drug resistance, toxicity, incomplete parasite eradication, reinfection, and poor patient tolerance*. These challenges highlight the need for *adjunctive and complementary approaches* that are safer, broader-acting, and more sustainable.

The paper focuses on *bioactive natural compounds* particularly *curcumin, resveratrol, and vitamin C* that demonstrate *direct antiparasitic activity*, along with *anti-inflammatory, antioxidant, and immune-modulating effects*. These compounds may enhance host defense, reduce parasite burden, and improve tolerance to pharmaceutical therapies.

Parasitic infections represent a significant and often underrecognized global health burden, affecting billions of individuals worldwide and contributing to substantial morbidity and mortality, particularly in vulnerable and resource-limited populations. These infections can impair immune function, disrupt gastrointestinal and metabolic health, and exacerbate chronic disease states, placing long-term strain on both individuals and healthcare systems. While conventional pharmaceutical antiparasitic therapies remain a cornerstone of treatment, their effectiveness is increasingly challenged by factors such as drug resistance, limited efficacy across parasite species, adverse side effects, and concerns related to overuse and misuse.

In response to these limitations, a growing body of scientific literature has begun to explore the role of naturally derived compounds as complementary or alternative strategies for parasite management. Bioactive plant compounds and micronutrients have demonstrated antiparasitic, anti-inflammatory, antioxidant, and immunomodulatory properties that may enhance host defense mechanisms while reducing treatment-related burden. This white paper examines the current scientific evidence supporting natural antiparasitic interventions, with specific focus on curcumin, resveratrol, and vitamin C. Emphasis is placed on their mechanisms of action, documented efficacy against parasitic organisms, and their potential role as adjunctive agents alongside conventional therapies, offering a more integrative and systems-based approach to parasite control.

The Global Burden of Parasitic Infections

Parasitic infections affect an estimated three billion people worldwide and remain a major global health challenge, with the highest burden occurring in regions lacking access to clean water, adequate sanitation, and healthcare infrastructure. These infections are broadly classified into three primary categories: protozoa, helminths, and ectoparasites. Protozoa are single-celled organisms responsible for diseases such as malaria, which alone causes more than 400,000 deaths annually, the majority occurring among young children in sub-Saharan Africa (CDC, 2024). Helminthic infections, including schistosomiasis and other soil-transmitted parasitic worms, are also highly prevalent, with an estimated 391 to 587 million individuals affected globally. The disease burden associated with helminth infections is substantial, accounting for approximately 24 to 56 million disability-adjusted life years (DALYs) lost worldwide (Hussein et al., 2017). Clinical manifestations of parasitic infections range from mild, nonspecific gastrointestinal symptoms to severe, life-threatening complications involving multiple organ systems. Common presentations include chronic diarrhea, abdominal pain, malnutrition, iron-deficiency anemia, and impaired growth and development. In more severe cases, parasitic infections may contribute to neurologic complications such as seizures and cognitive impairment (Cleveland Clinic, 2023). Populations at greatest risk include individuals living in developing countries, travelers to endemic regions, immunocompromised individuals, pregnant women, and young children, underscoring the urgent need for accessible, safe, and effective treatment strategies.

Limitations of Conventional Treatment

Current pharmaceutical treatment options for parasitic infections are associated with several significant limitations that restrict their long-term effectiveness and clinical utility. In the treatment of schistosomiasis, praziquantel is the primary and in many regions, the only widely used therapeutic agent. This reliance on a single drug raises serious concerns regarding the emergence of drug resistance. In addition, praziquantel demonstrates limited efficacy against juvenile worms and does not prevent reinfection, necessitating repeated treatment cycles and ongoing exposure to the drug (Hussein et al., 2017). Similarly, pharmacologic management of Chagas disease relies largely on nifurtimox and benznidazole, both of which exhibit variable and often limited efficacy, particularly in chronic infection. These agents are also associated with a high incidence of adverse effects, including nausea, vomiting, hypersensitivity reactions, and hepatotoxicity, frequently leading to poor adherence or treatment discontinuation (Puentes et al., 2018).

In the case of toxoplasmosis, combination therapy with pyrimethamine and sulfadiazine remains the standard of care; however, this regimen is associated with significant toxicity, including bone marrow suppression and gastrointestinal intolerance. As a result, many patients are unable to complete the full course of therapy, reducing overall treatment success (Chen et al., 2019). Collectively, these limitations underscore the urgent need for alternative or adjunctive therapeutic strategies that offer improved safety profiles, broader efficacy across parasite life stages, and reduced risk of resistance, thereby supporting more sustainable and accessible approaches to parasite management.

Curcumin: A Promising Natural Antiparasitic Agent

Curcumin is the key bioactive form of *Curcuma longa* (turmeric) that has entered the rank of the most studied natural antiparasitic drugs. This polyphenol molecule exhibits large-scale biological activities, including those of anti-inflammatory, antioxidant, and antiparasitic (de Paula Aguiar et al., 2016).

Mechanism of Action Against Schistosomiasis

Research on *Schistosoma mansoni* has determined that curcumin causes antiparasitic communities that operate over a multiplicity of mechanisms. It has been determined that the infestation load of the parasite worm is decreased by 49.3% and 38.4% at the end of a week and four weeks after infection, respectively (Hussein et al., 2017). The compound is a trigger of oxidative stress in adult worms by generating reactive oxygen species and depleting antioxidant defenses. Specifically, curcumin boosts superoxide dismutase activity and decreases the activity of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase which cause oxidation of proteins and parasite death (de Paula Aguiar et al., 2016). Ultrastructural examination shows that there are drastic morphologic al-

terations such as tegument damage, mitochondrial swelling and degeneration, and condensation of chromatin. The compound causes apoptotic-like processes in both female and male worms, which are characterized by DNA fragmentation, up-regulation of caspase 3/7, and caspase 3 activity (de Paula Aguiar et al., 2016). Combined with praziquantel, complete absence of adult worms is obtained, which implies possible combination therapy.

Effects on Hepatic Pathology

In addition to direct anti-parasitic action, curcumin exhibits positive action on infection-related pathology. Treatment also decreases the size of hepatic granuloma by 43.1 and granuloma count by 29.4 percent relative to untreated controls (Hussein et al., 2017). The histopathological analysis shows better liver tissue with less cloudy swelling and hydropic degeneration of hepatocytes. The mechanisms of such effects are probably due to the possibility of curcumin to regulate the expression of cytokines, especially tumor necrosis factor- α , interleukin-2, and interleukin-4.

Bioavailability Considerations

Although curcumin has a therapeutic potential, its poor water solubility and low bioavailability limit the clinical use of curcumin. Curcumin is more soluble and bioavailable in suspension in turmeric powder in olive oil (Hussein et al., 2017). Also, when curcumin is used together with non-curcuminoid constituents of turmeric, the bioavailability is enhanced 6.93 times. These methods of formulation are necessary in the translation of laboratory discoveries to clinically viable therapies.

Resveratrol: Dual Mechanisms of Antiparasitic Action

Resveratrol (3,4',5-trihydroxystilbene), which is a natural polyphenol in grapes, berries, and peanuts, has direct effects on parasites, and indirect effects on host immune response modulation.

Direct Antiparasitic Effects

Resveratrol *Toxoplasma gondii* studies show that it has direct antitoxoplasma activity with a 50% inhibitory concentration of 54.61 μM against extracellularly cultivated tachyzoites (Chen et al., 2019). The compound inhibits parasite population in a dose-dependent manner, with approximately 70% inhibition at 200 μM . The mechanistic studies indicate that resveratrol disrupts parasite redox homeostasis by markedly increasing superoxide dismutase activity and counterintuitive, decreasing the production of reactive oxygen species to unnaturally low levels (Pawlowska et al., 2023). This redox balance within the cell is fatal to parasites. The study of *Echinococcus granulosus protoscolices* confirms the wide antiparasitic spectrum of resveratrol. The compound causes dose- and time-dependent death, with a higher gamma-glutamyl transpeptidase activity (evidence of tegument damage) and a higher caspase-3 activity (evidence of apoptosis) (Ganji et al., 2022). Histopathological studies show that there are high levels of tissue changes and apoptosis in the treated hydatid cyst layers.

Indirect Effects Through Host Immunity

Resveratrol improves the removal of parasites by modulating the host immune response. Macrophages infected with *T. gondii* that are treated with resveratrol have a higher capability to kill intracellular parasites than their untreated counterparts (Chen et al., 2019). The compound relieves cellular stress load, induces proper apoptosis and preserves macrophage autophagic condition, thus acting indirectly to destroy intracellular parasites. The combination of this two-fold action, direct killing of parasites and increased host immunity, makes resveratrol an especially promising therapeutic agent.

Safety Profile

Resveratrol exhibits positive safety profiles. Cytotoxicity analysis reveals that resveratrol is not toxic but not very active at concentrations of 31.5 to 250 $\mu\text{g/ml}$, and only at 350 and 500 $\mu\text{g/ml}$, it becomes toxic (Ganji et al., 2022). This broad therapeutic index indicates possible clinical use with minimal host toxicity.

Vitamin C: Pro-oxidant and Antioxidant Properties

Antiparasitic effects of ascorbic acid (vitamin C) have a variety of mechanisms. Vitamin C is both an antioxidant at physiological levels (40-80 μ M) and a pro-oxidant at pharmacological levels (1-5 mM) (Puente et al., 2018).

Antiparasitic Activity Against Trypanosoma cruzi

The studies with *Trypanosoma cruzi* show that vitamin C has similar antiparasitic properties with benznidazole. Vitamin C is 1.3-1.8 times more active on epimastigotes than benznidazole, and on amastigotes, both agents demonstrate a similar IC₅₀ (Puente et al., 2018). The antiparasitic action of vitamin C is associated with the induction of oxidative stress by pro-oxidant activity. Treatment induces large, concentration-independent declines in parasite thiol content of about 50% in 2-5 hours, and compensatory increases which eventually are not enough to avoid parasite death (Puente et al., 2018). This redox homeostasis imbalance is fatal to parasites but harmless to host cells.

Combination Therapy Benefits

The real therapeutic effect of vitamin C appears when it is used in combination with traditional medicines. Although vitamin C has no antiparasitic effect on benznidazole against trypomastigotes, it substantially reduces the cytotoxicity of benznidazole on mammalian cells (Puente et al., 2018). Vitamin C alone decreases the number of parasites in infected mice compared to the controls. The antioxidant effect of vitamin C protects the host against treatment-related oxidative stress, leading to 100% survival and less weight loss during acute infection when the two compounds are used concomitantly. This protective impact indicates that vitamin C may be a significant adjuvant treatment.

Additional Natural Compounds with Antiparasitic Potential

Many plants have been shown to have antiparasitic activity through a variety of compounds produced by plants. Black seed oil (*Nigella sativa*) is a bioactive compound that is reported to have antimicrobial properties (Abbas et al., 2024). Sulfur-containing compounds present in the extracts of Garlic (*Allium sativum*) are active against various species of parasites by blocking the metabolism of the host (Arunsan et al., 2025). An anthelmintic effect of essential oils of fennel and other members of the Lamiaceae family is observed in vitro against schistosomes.

Other micronutrients have significant antiparasitic defense functions besides vitamin C. Zinc promotes the immune system and has been shown to have direct antiparasitic actions (Maywald & Rink, 2022). Vitamin D3, which is known to possess immunomodulatory effects, can be used to improve host resistance to parasitic infections (Golpour et al., 2019). Probiotic supplementation of healthy gut microbiota can be viewed as a valuable complementary measure because beneficial bacteria can compete with parasites over nutrients and improve the functioning of the intestinal barrier.

Clinical Considerations and Future Directions

The integration of natural compounds with conventional antiparasitic therapies warrants careful and systematic consideration. While a growing body of evidence supports the antiparasitic, anti-inflammatory, and immunomodulatory properties of many natural agents, their clinical translation is often limited by suboptimal bioavailability. Many phytochemicals exhibit poor solubility, rapid metabolism, or limited intestinal absorption, necessitating advanced formulation strategies to enhance their therapeutic potential (Garcia et al., 2025). In addition to formulation challenges, potential interactions between natural compounds and pharmaceutical agents must be thoroughly evaluated. Although concerns regarding herb-drug interactions are valid, certain natural compounds such as, vitamin C, have demonstrated favorable safety profiles and minimal interference with conventional antiparasitic drug efficacy or toxicity. In some cases, these compounds may even support treatment tolerance by mitigating oxidative stress and inflammation associated with pharmaceutical therapies.

Several critical research gaps remain and must be addressed to establish the efficacy and safety of integrative antiparasitic strategies in human populations. Large-scale, well-designed randomized controlled trials are essential to validate preclinical findings, determine optimal dosing strategies, and assess long-term outcomes. Furthermore, the exploration of novel delivery systems, including nanoformulations, liposomal encapsulation, and other advanced carrier technologies, offers a promising avenue to overcome bioavailability limitations and improve targeted delivery to affected tissues (Tiwari et al., 2023). Of particular interest is the potential activity of natural compounds against drug-resistant parasite strains. Unlike conventional antiparasitic agents, which often target a limited number of biochemical pathways, natural compounds may exert their effects through multiple mechanisms, including disruption of parasite metabolism, modulation of host immune responses, and interference with parasite signaling and replication pathways. These distinct mechanisms raise the possibility that natural compounds could complement existing therapies or provide alternative options in cases where resistance has compromised standard treatments. Collectively, these considerations highlight the importance of continued research into integrative and multi-modal approaches for sustainable parasite management.

References

1. Abbas M., et al. "Antimicrobial properties and therapeutic potential of bioactive compounds in *Nigella sativa*: A review". *Molecules* 29.20 (2024): 4914.
2. Arunsan P., et al. "Anthelmintic Activity and Pathophysiological Effect of *Allium sativum* Extract-Based Copper Nanoparticles Against the Carcinogenic Liver Fluke, *Opisthorchis viverrine*". *Journal of Parasitology Research* 2025.1 (2025): 7058749.
3. CDC. About Parasites (2024). <https://www.cdc.gov/parasites/about/index.html>
4. Chen QW., et al. "Direct and indirect inhibition effects of resveratrol against *Toxoplasma gondii* tachyzoites in vitro". *Antimicrobial Agents and Chemotherapy* 63.3 (2019): 10-1128.
5. Cleveland Clinic. Parasites (2023). <https://my.clevelandclinic.org/health/diseases/24911-parasites>
6. Cleveland Clinic. Parasitic Infection (2023). <https://my.clevelandclinic.org/health/diseases/24885-parasitic-infection>
7. de Paula Aguiar D., et al. "Curcumin generates oxidative stress and induces apoptosis in adult *Schistosoma mansoni* worms". *PLoS One* 11.11 (2016): e0167135.
8. Ganji A., et al. "Anti-parasitic effects of resveratrol on protoscolices and hydatid cyst layers". *Experimental Parasitology* 241 (2022): 108360.
9. García M, Magi MS and García MC. "Harnessing Phytonanotechnology to tackle neglected parasitic diseases: focus on Chagas disease and malaria". *Pharmaceutics* 17.8 (2025): 1043.
10. Golpour A, Bereswill S and Heimesaat MM. "Antimicrobial and immune-modulatory effects of vitamin D provide promising antibiotics-independent approaches to tackle bacterial infections—lessons learnt from a literature survey". *European Journal of Microbiology and Immunology* 9.3 (2019): 80-87.
11. Hussein A., et al. "Evaluation of the anti-schistosomal effects of turmeric (*Curcuma longa*) versus praziquantel in *Schistosoma mansoni* infected mice". *Iranian journal of parasitology* 12.4 (2017): 587.
12. Maywald M and Rink L. "Zinc in human health and infectious diseases". *Biomolecules* 12.12 (2022): 1748.
13. Pawłowska M., et al. "Oxidative stress in parasitic diseases—Reactive oxygen species as mediators of interactions between the host and the parasites". *Antioxidants* 13.1 (2023): 38.
14. Puente V., et al. "Anti-parasitic effect of vitamin C alone and in combination with benznidazole against *Trypanosoma cruzi*". *PLoS neglected tropical diseases* 12.9 (2018): e0006764.
15. Tiwari R., et al. "Nanotechnology-based strategies in parasitic disease management: from prevention to diagnosis and treatment". *ACS omega* 8.45 (2023): 42014-42027.